Company
Oxford Cannabinoid Technologies Holdings PLC
LON:OCTP
Oxford Cannabinoid Technologies Holdings PLC is a well-established, innovative and growing pharmaceutical company developing a portfolio of next generation prescription cannabinoid medicines for approval by key medicines regulatory agencies worldwide and targeting the multi-billion dollar pain market.
54 stories
Oxford Cannabinoid jumps on hints of cheaper cancer treatments
Oxford Cannabinoid formerly announced an expansion into oncology research on Monday
Oxford Cannabinoid Technologies names Paul Smalley as new finance director
Smalley has more than 25 years' UK and international financial experience including strategic management capabilities gained across a wide range of market sectors
Oxford Cannabinoid Technologies errs of the side of 'prudence' with budget review
The group is developing prescription cannabinoid medicines targeting the multi-billion dollar pain market
Oxford Cannabinoid holds first Scientific Advisory Board meeting
The SAB provided advice and guidance on the design of the company's upcoming Phase 1 clinical trials
Oxford Cannabinoid Technologies: Is the market underestimating its true potential?
“In our view, this is an interesting opportunity," said Dr John Savin, healthcare analyst at Proactive Research
Oxford Cannabinoid Technologies says two lead drugs will be in the clinic by Q1 2023
The company’s aim is to develop non-addictive, cannabinoid-based prescription pain medicines for “people who the opioid crisis has left behind”
Oxford Cannabinoid appoints Simbec-Orion to run first clinical trial on lead compound
Simbec-Orion has 45 years of specialist expertise in clinical pharmacology and lab expertise
Oxford Cannabinoid Technologies says lead assets are on track
The biopharmaceutical company is developing cannabinoid treatments to combat pain
Oxford Cannabinoid forms scientific advisory board
The initial focus will be on the design of the pharmaceutical company’s upcoming phase 1 clinical trials
Oxford Cannabinoid Technologies to focus neuropathic pain strategy on small fibre neuropathies
The company said there this a large unmet medical need in chemotherapy-induced peripheral neuropathy
Oxford Cannabinoid Technologies' preclinical study of lead asset returns encouraging pre-clinical results
OCT461201 was shown to reduce pain associated with chemotherapy-induced peripheral neuropathy
Oxford Cannabinoid makes progress on all drug development programmes
Research costs of early £1m went towards its four cannabinoid prescription drugs in the first half of its 2021 financial year
Oxford Cannabinoid adds Imperial Brands representative to board
The company also confirmed that Julie Pomeroy will take over as chair next month
Oxford Cannabinoid Technologies says financial results for half year in line with expectations as it updates on trial timelines
Investors were also provided with updated guidance on its two planned clinical programmes
Oxford Cannabinoid starts trading on OTCQB Market in US
“It will increase liquidity and significantly enhance the ability of US-based investors to access and trade OCTP shares.”
Oxford Cannabinoid Technologies brings in a specialist R&D firm to help it unlock the potential of Canopy Growth library
The end goal of the collaboration with the Canadian group Dalriada is to select two drug candidates ready for pre-clinical development by the end of next year
Archive
Proactive news headlines: Open Orphan, Bidstack Group, AFC Energy...
A glance at some of the day's highlights from the Proactive Investors newswire
Oxford Cannabinoid Technologies in drug development deal with Oxford StemTech
Stemtech will provide early-stage R&D data support
Oxford Cannabinoid chairman steps down over overdraft facility
Neil Mahapatra will stand down on 11 February 2022
Archive
Proactive News round-up: Oxford Cannabinoid Technologies, MGC Pharmaceuticals Ltd, Westmount, Challenger Energy …
A selection of the stories appearing today on the Proactive website
Oxford Cannabinoid considering ramifications of chairman's overdraft facility
Oxford Cannabinoid understands that Brown Shipley is unable to exercise its security over the pledged shares until July 2022, by which time KCP hopes to have removed the pledged shares from the legal charge
Oxford Cannabinoid Technologies sees good progress across all research programmes
"We believe that our management team, pipeline of drug candidates and network of partners, combined with the significant growth opportunity puts us on a strong footing," said chief executive Dr John Lucas.
Oxford Cannabinoid Technologies targets chronic pain condition with latest formulation
It will use a combination of unnamed phytocannabinoids to treat trigeminal neuralgia, which produces an “excruciating, stabbing, electric shock-like pain”
Archive
Proactive news headlines: Oxford Cannabinoid Technologies, Semper Fortis Esports, Plant Health Care, S&U...
A glance at some of the day's highlights from the Proactive Newswire
Oxford Cannabinoid Technologies hails Canopy Growth licensing deal
"Acquiring an exclusive licence to Canopy Growth's pharmaceutical cannabinoid derivative library is a significant achievement for the group and speaks volumes about our international reputation within our market,” said CEO, Dr John Lucas
Oxford Cannabinoid Technologies on track with plans
OTCP has applied for its shares to be listed on the US OTC QB market.
Oxford Cannabinoid Technologies hails progress following May IPO
The developer of cannabinoid-based prescription medicines said following the listing it had secured two commercial agreements which will “contribute significantly” to the development of its lead compound OCT461201
Oxford Cannabinoid aims to quicken pain treatment development with new partnership
The drug candidate will enter Evotec’s INDiGO programme, an integrated drug development process for accelerating early drug candidates to clinical trial stage, which has an anticipated duration of approximately 12 months
London’s listed cannabis sector doubles in size in first half of 2021
Another handful of new arrivals are due in the next few weeks
Shares in UK cannabis pain medicine developer spike on first day's dealings
The group had an initial valuation of just over £48mln at the issue price of 5p